Dr. Chengmo Yang is a Professor in the Department of Electrical and Computer Engineering at the University of Delaware, with a joint appointment. She received her PhD and MSc in Computer Science from the University of California, San Diego, and a BSc in Microelectronics from Peking University, China. PhD, University of California, San Diego MSc, University of California, San Diego BSc, Peking University, China Her research focuses on enhancing security, reliability, non-volatility, and energy efficiency in embedded systems, cyber-physical systems (CPS), and Internet-of-Things (IoT). She leads the Computer Architecture, Reliability, and Security (CARES) group and has authored over 70 peer-reviewed publications. Recent publications emphasize neural network accelerators, non-volatile memory (NVM) optimization, and security frameworks for embedded systems. Her work explores fault tolerance, wear leveling, and side-channel attack mitigation in NVM-based FPGAs, STT-RAM, and SSDs. National Science Foundation Career Award (2013) University of Delaware Mid-Career Faculty Excellence in Scholarship Award (2020) Best paper award at ICESS (2019) Three best paper nominations at DAC, DATE, and GLSVLSI (2019) Dr. Yang serves as Associate Editor for IEEE TCAD and ACM TODAES. She is the Diversity & Inclusion Representative for IEEE CEDA and has organized numerous conferences including Technical Program Chair for CODES-ISSS 2022. Her lab has hosted current and former students like Fanruo Meng (PhD candidate), Fateme Hosseini (Qualcomm), and Patrick Cronin (Intel), focusing on graduate-level research in hardware security and reliability.
Ana Klimovic is an Assistant Professor at the Department of Computer Science, ETH Zürich, and Deputy Head of the Institute for Computing Platforms. She leads the Efficient Architectures and Systems Lab (EASL) and focuses on optimizing cloud computing performance and resource efficiency. Education: Ph.D. in Electrical Engineering (Stanford University), M.S. in Electrical Engineering (Stanford), B.A.Sc. in Engineering Science (University of Toronto) Previous Roles: Research Scientist at Google Brain Her research spans cloud computing, operating systems, distributed systems, and their intersection with machine learning. Key areas include cloud-native programming models, elastic storage, GPU sharing, and data pipeline optimization. The 2025-2024 articles highlight trends in serverless computing, large language model (LLM) serving, GPU optimization, and data-centric ML systems. Themes include elasticity, resource multiplexing, heterogeneous computing, and infrastructure for AI/ML workloads. Scientific Awards: Microsoft Research PhD Fellowship, Stanford Graduate Fellowship She has led research projects on ephemeral storage, distributed training automation, and cost-efficient ML preprocessing, with grants from Microsoft Research and Stanford.
Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
David John Procter is a Professor of Organic Chemistry and Head of the Department of Chemistry at the University of Manchester. His career includes academic roles at the University of Glasgow (Lecturer, Senior Lecturer) and a Readership at the University of Manchester, where he became a Professor in 2008. His research focuses on developing new synthetic methods, catalysis, and materials chemistry, with applications in drug discovery, biocatalysis, and organic electronics. Education: BSc Chemistry (University of Leeds, 1992), PhD (1995, supervised by Prof. Christopher Rayner). Postdoctoral work: Florida State University (Prof. Robert Holton, Taxol analog synthesis). Research interests include samarium diiodide-mediated reactions, metal-free coupling processes, and sustainable synthesis methods. He leads projects funded by EPSRC, Industry (30 grants), and international collaborations. Awards include the EPSRC Established Career Fellowship (2015–2020), Bader Prize (2014), and Young Heterocyclic Chemist Award (2015). Key contributions: Total synthesis of natural products (e.g., pleuromutilin), development of copper-catalyzed multicomponent couplings, and innovative methods for organic materials. His work aligns with UN Sustainable Development Goals related to affordable and clean energy and responsible consumption. Collaborations span academic and industrial partnerships in chemistry, physics, and biology. He supervises 60+ students and contributes to the Organic Materials Innovation Centre (OMIC). His group’s research is detailed at proctergroupresearch.com .
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Lindsey Draper, MD serves as an Adjunct Instructor in the Roybal Laboratory within the Department of Medicine, Division of Hematology and Oncology at the University of California San Francisco School of Medicine. Her clinical practice focuses on the treatment of patients with recurrent ovarian cancer using systemic therapies including chemotherapy and immunotherapy, with a commitment to evaluating and offering clinical trial opportunities as part of individualized patient care. Dr. Draper completed her educational training with a B.S. in Biology from Juniata College (2010), an M.D. from the University of Maryland School of Medicine (2017), an Internal Medicine Residency at The Mount Sinai Hospital (2022), and is currently completing a Medical Oncology Fellowship at UCSF (2025-2027). Her research interests center on cancer immunotherapy, particularly T cell-based approaches for HPV-associated cancers and ovarian cancer. She investigates engineered T cell therapies targeting viral antigens in cervical and other HPV-related cancers, with a focus on overcoming treatment resistance and improving clinical outcomes through novel immunotherapeutic strategies. Her work bridges fundamental immunological mechanisms with clinical applications, emphasizing the translation of laboratory discoveries into patient treatments. Dr. Draper's publication record demonstrates consistent contributions to the field of cancer immunotherapy, with recent work focusing on TCR-engineered T cells for leukemia and HPV-associated malignancies. Her research trajectory shows increasing sophistication in T cell engineering approaches and a growing emphasis on addressing inflammatory responses and treatment resistance mechanisms. Parker Institute for Cancer Immunotherapy Early Career Research Award: Parker Scholar (2024) Gladstone-UCSF Institute of Genomic Immunology Symbiont Seed Grant for 'Antigen Discovery for Ovarian Cancer' (2024) Conquer Cancer Young Investigator Award, American Society of Clinical Oncology (2024) Women in Cancer Immunotherapy Network Leadership Institute Selected Participant, Society for Immunotherapy of Cancer (2024) Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco (2023-2025) As a physician-scientist, Dr. Draper maintains an active research program while providing clinical care, with particular emphasis on developing novel immunotherapies for gynecologic cancers. Her current fellowship at UCSF and multiple early-career awards indicate strong potential for continued contributions to the field of cancer immunotherapy. Dr. Draper works within the Roybal Laboratory at UCSF, which focuses on innovative approaches to cancer immunotherapy and T cell engineering. Her research intersects with multiple collaborative initiatives at UCSF, including the Parker Institute for Cancer Immunotherapy and the Gladstone-UCSF Institute of Genomic Immunology.
Réka Albert is a Distinguished Professor of Physics at Pennsylvania State University, affiliated with the Eberly College of Science. Her research focuses on the application of network science to biological systems, including signal transduction networks, ecological interactions, and cancer systems biology. She holds editorial roles at npj Systems Biology and Applications , IET Systems Biology , and Bulletin of Mathematical Biology . Education: Ph.D. in Physics from the University of Notre Dame (2001), M.S. and B.S. from Babeș-Bolyai University, Romania (1995-1996). Research Interests: Modeling complex systems using network theory; Boolean network analysis of biological pathways; ecological community dynamics; systems-level understanding of disease mechanisms (e.g., cancer, AML). Her work bridges theoretical physics, computational biology, and experimental data to predict system behavior and therapeutic strategies. Awards: External member of the Hungarian Academy of Sciences (2016), APS Maria Goeppert-Mayer Award (2011), NSF CAREER Award (2007), and Alfred P. Sloan Fellowship (2004). Grants/Support: NSF awards (MCB 1715826, IIS 1814405), ARO MURI on hyperuniform systems, and collaborations with biologists like Sarah Assmann (plant signaling) and Katriona Shea (ecology). Labs/Teams: Leads a multidisciplinary research group at Penn State, mentoring over 20 PhD alumni and current students like Eli Newby and Fatemeh Nasrollahi. Active in developing tools like pystablemotifs for Boolean network analysis.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Harri Lähdesmäki is an Associate Professor (tenured) at the Department of Computer Science, Aalto University, where he leads the Computational Systems Biology research group. His work focuses on probabilistic machine learning and deep generative models with applications in biomedicine and molecular biology. Key Research Interests: Probabilistic machine learning, deep generative models, computational biology, bioinformatics, longitudinal data modeling Contact: harri.lahdesmaki@aalto.fi | Konemiehentie 2, 02150 Espoo, Finland His recent publications highlight advancements in: Gaussian process priors for scalable deep generative models Single-cell analysis of immune repertoires in leukemia and diabetes Probabilistic deconvolution methods for RNA-seq data Epigenetic analysis using hidden Markov and mixed models Transformer-based survival prediction and missing data handling Harri’s work integrates mechanistic modeling with Bayesian inference, particularly applied to immunology, cancer biology, and early disease prediction.
Jingtong Hu is an Associate Professor at the Swanson School of Engineering, University of Pittsburgh, where he also holds the William Kepler Whiteford Faculty Fellowship. His research focuses on Cyber-Physical Systems and Infrastructure Security, with significant contributions to embedded systems, non-volatile memory architectures, and hardware/software co-design for energy-constrained environments. Dr. Hu received his PhD from the University of Texas at Dallas (2007-2013) and his Bachelor of Engineering from Shandong University (2003-2007). His research spans multiple interdisciplinary areas including energy harvesting systems, non-volatile processors, FPGA acceleration, and machine learning at the edge. His recent publications demonstrate a strong focus on algorithm-hardware co-design, particularly for vision transformers, federated learning, and non-volatile memory systems. His work often addresses the challenges of implementing AI on resource-constrained edge devices, with emphasis on energy efficiency, reliability, and performance optimization. The trend in his publications shows increasing focus on sustainable AI processing, heterogeneous computing architectures, and personalized machine learning for IoT applications. Selected Awards: IEEE Transactions on Computer-Aided Design Donald O. Pederson Best Paper Award (2021) ACM SIGDA Meritorious Service Award (2019) Multiple Best Paper Award nominations at top conferences including DAC, ASP-DAC, and CODES+ISSS Dr. Hu's research has been supported by multiple grants focusing on energy-efficient computing, non-volatile memory systems, and hardware acceleration for machine learning. His collaborative work spans numerous institutions and involves interdisciplinary teams working at the intersection of computer architecture, embedded systems, and artificial intelligence. His publications show extensive collaboration with researchers at the University of Pittsburgh, particularly with Albert K. Jones and Yiyu Shi. His laboratory work focuses on implementing practical systems for energy harvesting powered devices, non-volatile processors, and hardware accelerators for machine learning applications. Current projects appear to emphasize sustainable AI processing at the edge, heterogeneous FPGA acceleration, and personalized federated learning for health monitoring applications.
